UroGen invests up to $7 million in IntraGel equity
URGN•Separate option for TumoCure
A separate option covers worldwide rights to TumoCure for advanced head and neck cancer, exercisable following completion of a Phase 2 study.
Equity investment and strategic collaboration
UroGen Pharma entered an equity investment agreement with IntraGel Therapeutics to invest up to $7 million in IntraGel securities.
The investment is tied to a strategic collaboration that grants options to license IntraGel’s SRGel platform for up to three oncology products.
